OJVM  Vol.2 No.4 , December 2012
In Vitro Characterization of Docetaxel as a Radiosensitizer in Canine and Feline Cancer Cell Lines
Abstract: An In Vitro study was conducted to investigate docetaxel as a radiation sensitizer in four canine (mammary carcinoma—CMT12 and CMT25, osteosarcoma—OS2.4, and transitional cell carcinoma—PTCC), and one feline cancer cell line (oral squamous cell carcinoma—SCCF1) to provide a basis for combination therapy in clinical patients. Cells were exposed to docetaxel followed by a single dose of radiation. The percent surviving fraction was determined by MTT assay. The combination index (CI) method determined synergistic cytotoxicity for the CMT12, CMT25 and OS2.4 cell lines with median CI values of 0.35, 0.47, 0.63 respectively. The SCCF1 cell line had moderate synergistic cytotoxicity with a median CI of 0.76, while the PTCC cell line resulted in antagonistic cytoxicity with a median CI of 2.75. The results indicated that docetaxel was a radiation sensitizer in 4 out of the 5 cancer cell lines tested.
Cite this paper: C. E. Balkman, T. L. Gieger, M. M. Zgola, L. D. Lewis and M. C. McEntee, "In Vitro Characterization of Docetaxel as a Radiosensitizer in Canine and Feline Cancer Cell Lines," Open Journal of Veterinary Medicine, Vol. 2 No. 4, 2012, pp. 285-292. doi: 10.4236/ojvm.2012.24045.

[1]   V. Bregazzi, S. M. LaRue, E. McNiel, D. W. Macy, W. S. Dernell, B. E. Powers and S. J. Withrow, “Treatment with a Combination of Doxorubicin, Surgery, and Radiation Versus Surgery and Radiation Alone for Cats with Vaccine-Associated Sarcoma: 25 Cases (1995-2000),” Journal of the American Veterinary Medical Association, Vol. 218, No. 4, 2001, pp. 547-550. doi:10.2460/javma.2001.218.547

[2]   T. Kobayashi, M. L. Hauck, R. Dodge, R. L. Page, G. S. Price, L. E. Williams, E. M. Hardie, K. G. Mathews and E. D. Thrall, “Preoperative Radiotherapy for Vaccine Associated Sarcoma In 92 Cats,” Veterinary Radiology & Ultrasound, Vol. 43, No. 5, 2002, pp. 473-479. doi:10.1111/j.1740-8261.2002.tb01036.x

[3]   K. P. Freeman, K. A. Hahn, F. D. Harris and G. K. King, “Treatment of Dogs with Oral Melanoma by Hypofractionated Radiation Therapy and Platinum-Based Chemotherapy (1987-1997),” Journal of Veterinary Internal Medicine, Vol. 17, No. 1, 2003, pp. 96-101.

[4]   M. M. Turek, L. J. Forrest, W. M. Adams, S. C. Helfand and D. M. Vail, “Postoperative Radiotherapy and Mitoxantrone for Anal Sac Adenocarcinomas in the Dog: 15 Cases (1991-2001),” Veterinary and Comparative Oncology, Vol. 1, No. 2, 2003, pp. 94-104. doi:10.1046/j.1476-5829.2003.00013.x

[5]   S. E. Lana, W. S. Dernell, M. H. Lafferty, S. J. Withrow and S. M. LaRue, “Use of Radiation and a Slow-Release Cisplatin Formulation for Treatment of Canine Nasal Tumors,” Veterinary Radiology & Ultrasound, Vol. 45, No. 6, 2004, pp. 577-581. doi:10.1111/j.1740-8261.2004.04100.x

[6]   M. E. Nadeau, B. E. Kitchell, R. L. Rooks and S. M. LaRue, “Cobalt Radiation with or Without Low-Dose Cisplatin for Treatment of Canine Naso-Sinus Carcinomas,” Veterinary Radiology & Ultrasound, Vol. 45, No. 4, 2004, pp. 362-367. doi:10.1111/j.1740-8261.2004.04068.x

[7]   K. A. Hahn, M. N. Endicott, G. K. King and F. D. Harris-King, “Evaluation of Radiotherapy Alone or in Combination with Doxorubicin Chemotherapy for the Treatment of Cats with Incompletely Excised Soft Tissue Sarcomas: 71 Cases (1989-1999),” Journal of the American Veterinary Medical Association, Vol. 231, No. 5, 2007, pp. 742-745. doi:10.2460/javma.231.5.742

[8]   D. Simon D, J. W. Knebel, W. Baumg?rtner, M. Aufderheide, A. Meyer-Lindenberg and I. Nolte, “In Vitro Efficacy of Chemotherapeutics as Determined by 50% Inhibitory Concentrations in Cell Cultures of Mammary Gland Tumors Obtained from Dogs,” American Journal of Veterinary Research, Vol. 62, No. 11, 2001, pp. 1825-1830. doi:10.2460/ajvr.2001.62.1825

[9]   L. E. Williams, N. Banerji, J. S. Klausner, V. Kapur and S. Kanjilal, “Establishment of Two Vaccine-Associated Feline Sarcoma Cell Lines and Determination of in Vitro Chemosensitivity to Doxorubicin and Mitoxantrone,” American Journal of Veterinary Research, Vol. 62, No. 9, 2001, pp. 1354-1357. doi:10.2460/ajvr.2001.62.1354

[10]   N. Banerji, X. Li, J. S. Klausner, V. Kapur and S. Kanjilal, “Evaluation of in Vitro Chemosensitivity of Vaccine-Associated Feline Sarcoma Cell Lines to Vincristine and Paclitaxel,” American Journal of Veterinary Research, Vol. 63, No. 5, 2002, pp. 728-732. doi:10.2460/ajvr.2002.63.728

[11]   R. Katayama, M. K. Huelsmeyer, A. K. Marr, I. D. Kurzman, D. H. Thamm and D. M. Vail, “Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Activity and Increases Chemosensitivity in Feline Vaccine-Associated Sarcoma,” Cancer Chemotherapy and Pharmacology, Vol. 54, No. 1, 2004, pp. 25-33. doi:10.1007/s00280-004-0780-7

[12]   S. D. Hafeman, D. Varland and S. W. Dow, “Bisphosphonates Significantly Increase the Activity of Doxorubicin or Vincristine against Canine Malignant Histiocytosis Cells,” Veterinary and Comparative Oncology, Vol. 10, No. 1, 2011, pp. 44-56. doi:10.1111/j.1476-5829.2011.00274.x

[13]   N. K. Thudi, S. T. Shu, C. K. Martin, L. G. Lanigan, M. V. P. Nadella, A. Van Bokhoven, J. L. Webeck, J. K. Simmons, S. Murahari, W. C. Kisseberth, M. Breen, C. Williams, C. S. Chen, L. K. McCauley, E. T. Keller and T. J. Rosol, “Development of a Brain Metastatic Canine Prostate Cancer Cell Line,” The Prostate, Vol. 71, No. 12, 2011, pp. 1251-1263.

[14]   F. Lavelle, M. C. Bissery, C. Combeau, J. F. Riou, P. Vrignaud and S. André, “Preclinical Evaluation of Docetaxel (Taxotere),” Seminars in Oncology, Vol. 22, No. 6 Suppl. 13, 1995, pp. 3-16.

[15]   A. L. Dunne, C. Mothersill, T. Robson, G. D. Wilson and D. G. Hirst, “Radiosensitization of Colon Cancer Cell Lines by Docetaxel: Mechanisms of Action,” Oncology Research, Vol. 14, No. 9, 2004, pp. 447-454.

[16]   G. P. Amorino, V. M. Hamilton and H. Choy, “ Enhancement of Radiation Effects by Combined Docetaxel and Carboplatin Treatment in Vitro,” Radiation Oncology Investigations, Vol. 7, No. 6, 1999, pp. 343-352 doi:10.1002/(SICI)1520-6823(1999)7:6<343::AID-ROI4>3.0.CO;2-C

[17]   H. L. Lin, T. Y. Liu, G. Y. Chau, W. Y. Liu and C. W. Chi, “Comparison of 2-Methoxyestradiol-Induced, Docetaxel-Induced, and Paclitaxel-Induced Apoptosis in Hepatoma Cells and Its Correlation with Reactive Oxygen Species,” Cancer, Vol. 89, No. 5, 2000, pp. 983-994. doi:10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.0.CO;2-G

[18]   D. R. Budman and A. Calabro, “In Vitro Search for Synergy and Antagonism: Evaluation of Docetaxel Combinations in Breast Cancer Cell Lines,” Breast Cancer Research and Treatments, Vol. 74, No. 1, 2002, pp. 41-46. doi:10.1023/A:1016070230538

[19]   L. Milas, M. M. Milas and K. A. Mason, “Combination of Taxanes with Radiation: Preclinical Studies,” Seminars in Radiation Oncology, Vol. 9, No. 2 Suppl. 1, 1999, pp. 12-26.

[20]   L. Milas, “Docetaxel/Radiation Combinations: Rationale and Preclinical Findings,” Clinical Lung Cancer, Vol. 3, No. Suppl. 2, 2002, pp. S29-S36.

[21]   D. S. Grant, T. L. Williams, M. Zahaczewsky and A. P. Dicker, “Comparison of Antiangiogenic Activities Using Paclitaxel (Taxol) and Docetaxel (Taxotere),” International Journal of Cancer, Vol. 104, No. 1, 2003, pp. 121-129. doi:10.1002/ijc.10907

[22]   T. W. Synold, I. Dussault, B. M. Forman, “The Orphan Nuclear Receptor SXR Coordinately Regulates Drug Metabolism and Efflux,” Nature Medicine, Vol. 7, No. 5, 2001, pp. 584-590. doi:10.1038/87912

[23]   C. Hennequin, N. Giocanti and V. Frenette, “Interaction of Ionizing Radiation with Paclitaxel (Taxol) and Docetaxel (Taxotere) in HeLa and SQ20B Cells,” Cancer Research, Vol. 56, No. 8, 1996, pp. 1842-1850.

[24]   O. Pradier, M. Rave-Frank, J. Lehmann, E. Lücke, O. Boghun, C. F. Hess and H. Schmidberger, “Effects of Docetaxel in Combination with Radiation on Human Head and Neck Cancer Cells (ZMK-1) and Cervical Squamous Cell Carcinoma Cells (CASKI),” International Journal of Cancer, Vol. 91, No. 6, 2001, pp. 840-845. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1142>3.0.CO;2-U

[25]   K. A. Mason, N. R. Hunter, M. Milas, J. L. Abbruzzese and L. Milas, “Docetaxel Enhances Tumor Radioresponse in Vivo,” Clinical Cancer Research, Vol. 3, No. 12 pt. 1, 1997, pp. 2431-2438.

[26]   K. A. Mason, K. Kishi, N. Hunter, L. Buchmiller, T. Akimoto, R. Kumaki, L. Milas, “Effect of Docetaxel on the Therapeutic Ratio of Fractionated Radiotherapy in Vivo,” Clinical Cancer Research, Vol. 5, No. 12, 1999, pp. 4191-4198.

[27]   R. B. Tishler, C. M. Norris, A. D. Colevas, C. C. Lamb, D. Karp, P. M. Busse, A. Nixon, B. Lake-Willcutt, R. Costello, M. Case and M. R. Posner, “A Phase I/II Trial of Concurrent Docetaxel and Radiation After Induction Chemotherapy in Patients with Poor Prognosis Squamous Cell Carcinoma of the Head and Neck,” Cancer, Vol. 95, No. 7, 2002, pp. 1472-1481. doi:10.1016/S0360-3016(03)01370-1

[28]   G. Calais, E. Bardet, C. Sire, M. Alfonsi, J. Bourhis, B. Rhein, J. Tortochaux, Y. T. Man, H. Auvray and P. Garaud, “Radiotherapy with Concomitant Weekly Docetaxel for Stages III/IV Oropharynx Carcinoma. Results of the 98-02 Gortec Phase II Trial,” International Journal of Radiation Oncology Biology and Physics, Vol. 58, No. 1, 2004, pp. 161-166. doi:10.1016/S0360-3016(03)01370-1

[29]   S. D. Baker, M. Zhao, C. K. Lee, J. Verweij, Y. Zabelina, J. R. Brahmer, A. C. Wolff, A. Sparreboom and M. A. Carducci, “Comparative Pharmacokinetics of Weekly and Every-Three-Week Docetaxel,” Clinical Cancer Research, Vol. 10, No. 6, 2004, pp. 1976-1983. doi:10.1158/1078-0432.CCR-0842-03

[30]   P. Kumar, M. Perrotti, R. Weiss, M. Todd, S. Goodin, K. Cummings and R. S. DiPaola, “Phase I Trial of Weekly Docetaxel with Concurrent Three-Dimensional Conformal Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate,” Journal of Clinical Oncology, Vol. 22, No. 10, 2004, pp. 1909-1915. doi:10.1200/JCO.2004.02.001

[31]   M. Fujii, M. Tsukuda, B. Satake, A. Kubota, A. Kida, N. Kohno, K. Okani and Y. Inuyama, “Phase I/II Trial of Weekly Docetaxel and Concomitant Radiotherapy for Squamous Cell Carcinoma of the Head and Neck,” International Journal of Clinical Oncology, Vol. 9, No. 2, 2004, pp. 107-112. doi:10.1007/s10147-003-0375-z

[32]   A. F. Kovács, S. Mose, H. D. B?ttcher and K. Bitter, “Multimodality Treatment Including Postoperative Radiation and Concurrent Chemotherapy with Weekly Docetaxel Is Feasible and Effective in Patients with Oral and Oropharyngeal Cancer,” Strahlentherapie und Onkologie, Vol. 181, No. 1, 2005, pp. 26-34. doi:10.1007/s00066-005-1272-3

[33]   A. Barnadas, R. Mesía, M. Majem, R. Galiana, A. López-Pousa, J. M. de Vega, M. Margelí, V. Valentí, L. Anglada, A. Lloansí and A. Arellano, “Phase I/II Docetaxel Plus Concurrent Hyperfractionated Radiotherapy in Locally Advanced Unresectable Head and Neck Cancer,” Clinical & Translational Oncology, Vol. 13, No. 4, 2011, pp. 254-260.

[34]   M. C. McEntee, K. M. Rassnick, L. D. Lewis, M. M. Zgola, B. B. Beaulieu, C. E. Balkman and R. L. Page, “Phase I and Pharmacokinetic Evaluation of Oral Docetaxel and Cyclosporin A in Tumor-Bearing Dogs,” American Journal of Veterinary Research, Vol. 67, No. 6, 2006, pp. 1057-1062. doi:10.2460/ajvr.67.6.1057

[35]   M. C. McEntee, K. M. Rassnick, D. B. Bailey, C. E. Balkman, J. L. Flanagan, B. B. Beaulieu, M. M. Zgola, L. D. Lewis and R. L. Page, “Phase I and Pharmacokinetic Evaluation of the Combination of Orally Administered Docetaxel and Cyclosporin A in Tumor-Bearing Cats,” Journal of Veterinary Internal Medicine, Vol. 20, No. 6, 2006, pp. 1370-1375. doi:10.1111/j.1939-1676.2006.tb00753.x

[36]   A. Waite, C. Balkman, D. Bailey, M. Kiselow, A. Flory, B. Beaulieu, L. Lewis, M. McEntee, “Phase II Study of Oral Docetaxel and Cyclosporine in Canine Epithelial Cancer,” Veterinary and Comparative Oncology, 2012, (in press). doi:10.1111/j.1476-5829.2012.00350.x

[37]   T. C. Chou and P. Talalay, “Quantitative Analysis of Dose-Effect Relationships: the Combined Effects of Multiple Drugs or Enzyme Inhibitors,” Advances in Enzyme Regulation, Vol. 22, 1984, pp. 27-55. doi:10.1016/0065-2571(84)90007-4

[38]   C. E. Leonard, D. C. Chan, T. C. Chou, R. Kumar and P. A. Bunn, “Paclitaxel Enhances in Vitro Radiosensitivity of Squamous Carcinoma Cell Lines of the Head and Neck,” Cancer Research, Vol. 56, No. 22, 1996, pp. 5198-5204.

[39]   T. C. Chou, “The Median-Effect Principle and the Combination Index for Quantitation of Synergism and Antagonism,” In: T. C. Chou and D. C. Rideout, Eds., Synergism and Antagonism in Chemotherapy, Academic Press, San Diego, CA, 1991, pp. 61-102.

[40]   S. Haldar, A. Basu and C. M. Croce, “Bcl-2 Is the Guardian of Microtubule Integrity,” Cancer Research, Vol. 57, No. 2, 1997, pp. 229-233.

[41]   C. J. Sweeny, K. D. Miller, S. E. Sissons, S. Nozaki, D. K. Heilman, J. Shen and G. W. Sledge, “The Antiangiogenic Property of Docetaxel Is Synergistic with A Recombinant Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor or 2-Methoxyestradiol but Antagonized by Endothelial Growth Factors,” Cancer Research, Vol. 61, No. 8, 2001, pp. 3369-3372.

[42]   A. Vacca, D. Ribatti, M. Iurlaro, F. Merchionne, B. Nico, R. Ria and F. Dammacco, “Docetaxel Versus Paclitaxel for Antiangiogenesis,” Journal of Hematotherapy & Stem Cell Research, Vol. 11, No. 1, 2002, pp. 103-118. doi:10.1089/152581602753448577

[43]   K. A. Hotchkiss, A. W. Ashton, R. Mahmood, R. G. Russell, J. A. Sparano and E. L. Schwartz. “Inhibition of Endothelial Cell Function in Vitro and Angiogenesis in Vivo by Docetaxel (Taxotere): Association with Impaired Repositioning of the Microtubule Organizing Center,” Molecular Cancer Therapeutics, Vol. 1, No. 13, 2002, pp. 1191-1200.

[44]   M. Muta, T. Yanagawa, Y. Sai Y, S. Saji, E. Suzuki, T. Aruga, K. Kuroi, G. Matsumoto, M. Toi and E. Nakashima, “Effect of Low-Dose Paclitaxel and Docetaxel on Endothelial Progenitor Cells,” Oncology, Vol. 77, No. 3-4, 2009, pp. 182-191. doi:10.1159/000236016

[45]   P. D. Jones, L. P. de Lorimier, B. E. Kitchell and J. M. Losonsky, “Gemcitabine as a Radiosensitizer for Nonresectable Feline Oral Squamous Cell Carcinoma,” Journal of the American Animal Hospital Association, Vol. 39, No. 5, 2003, pp. 463-467.

[46]   A. K. LeBlanc, T. A. LaDue, J. M. Turrel and M. K. Klein, “Unexpected Toxicity Following Use of Gemcitabine as a Radiosensitizer in Head and Neck Carcinomas: A Veterinary Radiation Therapy Oncology Group Pilot Study,” Veterinary Radiology & Ultrasound, Vol. 45, No. 5, 2004, pp. 466-470. doi:10.1111/j.1740-8261.2004.04080.x

[47]   M. R. Posner, et al., “Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer,” The New England Journal of Medicine, Vol. 357, No. 17, 2007, pp. 1705-1715. doi:10.1056/NEJMoa070956

[48]   M. Tsukuda, et al., “Randomized Controlled Phase II Comparison Study of Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus CCRT with Cisplatin, 5-Fluorouracil, Methotrexate and Leucovorin in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck,” Cancer Chemotherapy and Pharmacology, Vol. 66, No. 4, 2010, pp. 729-736. doi:10.1007/s00280-009-1217-0